Semaglutide for Weight Loss Cost (2026)

Brand-name Wegovy retails at approximately $1,300 per month without insurance in 2026. Compounded semaglutide from licensed 503A pharmacies through telehealth weight-loss clinics typically runs $199 to $499 per month, a 60 to 85 percent discount. With insurance coverage for Wegovy, out-of-pocket can be $0 to $50 with prior authorization. Medicare does not cover for obesity but does cover Ozempic for type 2 diabetes.

Published clinical trials show average weight loss of 12 to 17 percent of starting body weight at 68 weeks on the maximum dose (2.4 mg/week). For a 220-pound starting weight, that is approximately 26 to 37 pounds. Results vary significantly: some patients lose 25+ percent, others lose under 5 percent. Roughly 85 percent of patients achieve at least 5 percent weight loss; about 50 percent achieve at least 15 percent.

Compounded semaglutide from licensed 503A pharmacies using FDA-approved active pharmaceutical ingredients is widely considered safe by clinicians, though it carries less manufacturing oversight than brand-name Wegovy. Risks include variable potency, contamination, and use of unapproved "salt forms" (semaglutide acetate or sodium) by lower-quality compounders. Verify your clinic uses an FDA-registered 503A pharmacy and asks about API source. Avoid pharmacies that cannot provide certificate of analysis.

Studies show 60 to 70 percent of weight lost on semaglutide is regained within 12 to 24 months of stopping. Most patients require ongoing maintenance dosing (often at reduced dose) to maintain weight loss long-term, or robust lifestyle changes including resistance training, structured nutrition, and behavioral support. Semaglutide is generally considered a long-term or indefinite medication for chronic weight management, similar to medications for high blood pressure or diabetes.

The most common side effects are gastrointestinal: nausea (30-45 percent), constipation (20-30 percent), diarrhea (15-25 percent), and vomiting (15-25 percent). Side effects are typically mild to moderate and most pronounced during dose increases, then subside over 1-2 weeks at each dose level. Rare but serious side effects include gallbladder disease (1-2 percent), pancreatitis (less than 0.5 percent), and theoretical risk of thyroid C-cell tumors (not confirmed in humans).

Approximately 25 to 40 percent of weight lost on semaglutide is lean mass (muscle, organ tissue, connective tissue) rather than fat, similar to the muscle loss seen with severe calorie restriction. Resistance training 2-3 times per week and adequate protein intake (1.0-1.2 grams per kg body weight) during semaglutide use substantially mitigate muscle loss. Some clinics now bundle nutritional and exercise coaching for this reason.

Alcohol is not contraindicated with semaglutide but is often poorly tolerated. Many patients report dramatically reduced alcohol cravings and tolerance on GLP-1 medications - a phenomenon currently being studied as a potential therapy for alcohol use disorder. Some patients report intensified hangovers or stomach upset from drinking on semaglutide.

Coverage varies widely. Many commercial insurance plans cover Wegovy for obesity (BMI 30+) with prior authorization, often requiring documented attempts at lifestyle change. Medicare does not cover Wegovy for obesity but covers Ozempic for diabetes. Medicaid coverage varies by state. Some employers exclude obesity medications from formularies. Compounded semaglutide is generally not covered by insurance.

Semaglutide is injected subcutaneously (under the skin, not into muscle) once weekly. Common injection sites are the abdomen (at least 2 inches from the navel), the front of the thigh, or the back of the upper arm. Brand-name Wegovy comes in pre-filled pens with a fixed dose; compounded semaglutide is typically drawn from a multi-dose vial into a syringe.

All three contain the same active molecule (semaglutide). Wegovy is FDA-approved for weight management at doses up to 2.4 mg/week. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg/week. Compounded semaglutide is prepared by 503A pharmacies in custom dosing, typically in multi-dose vials. Brand-name products are manufactured under FDA pharmaceutical standards; compounded versions are subject to USP compounding standards which are similar but not identical.

Semaglutide is not approved for type 1 diabetes and is generally not recommended due to risk of severe hypoglycemia when combined with insulin. Always discuss with your endocrinologist before considering GLP-1 medication if you have type 1 diabetes.

Semaglutide is a single-agonist GLP-1 medication. Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) is a dual-agonist targeting both GLP-1 and GIP receptors. Tirzepatide shows slightly greater average weight loss in trials (18-22 percent vs 12-17 percent for semaglutide). Both have similar side effect profiles and similar pricing structures (brand $1,000-$1,300/month, compounded $200-$500/month).

Most patients report stable or improved mood on semaglutide. Some report transient low mood, particularly during titration. There have been case reports and ongoing investigation of rare suicidal ideation reports on GLP-1 medications, though large studies have not confirmed a causal relationship. Discuss with your provider if you have a history of severe depression or suicidality.